Empire Genomics Partners With KromaTiD to Offer More Robust Solutions for Detecting Oncology Abnormalities

2017-11-15 15:11:51

Empire Genomics announced today that it has entered into a new strategic partnership with KromaTiD to provide a comprehensive offering that helps researchers and clinicians better understand the genomic abnormalities of cancer patients.

Empire Genomics CEO Anthony Johnson stated “KromaTiD’s Pinpoint FISH probes are a perfect complement to our existing FISH probe portfolio, allowing us to design novel probes for areas with cross homology and/or target regions only a few kilobases in size.”

The partnership also pairs Empire Genomics’ Next-Gen Sequencing (NGS) services and CLIA-certified laboratory with KromaTiD’s new directional Genomic Hybridization (dGH™) technology. A tool which can be used in complement with NGS to detect and confirm structural aberrations such as inversions at the single cell level, something not detectable with Next-Gen Sequencing alone. KromaTiD President and GM, Christopher Tompkins, added “By combining our dGH technology with Empire Genomics’ portfolio of BAC FISH probes and their suite of molecular testing services, including Sanger and Next-Gen Sequencing, we can now analyze the simplest SNP to the most complex, heterogeneous fusion gene".

Precision medicine requires genomic detection at a variety of resolutions and the combined offerings of Empire Genomics and KromaTiD will now provide researchers and clinicians with the most comprehensive suite of genomic services available in the market today.